Clinical trial
Expanded Access Study of Iodine-131 Anti-B1 Antibody
NCT00022958 · Corixa Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00022958 |
|---|---|
| Title | Expanded Access Study of Iodine-131 Anti-B1 Antibody |
| Official title | Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | Corixa Corporation, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Iodine-131 Anti-B1 Antibody |
| Start date | Sep 1, 1998 |
| First posted | Aug 20, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: